Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfβ in osteosarcoma cells

Journal of Cellular Physiology

Volumn 221, Issue 3, 2009, Pages 560-571

  San Martin, Inga A ^a   Varela, Nelson ^a   Gaete, Marcia ^a   Villegas, Karina ^a   Osorio, Mariana ^a   Tapia, Julio C ^a   Antonelli, Marcelo ^a   Mancilla, Edna E ^b   Pereira, Barry P ^d   Nathan, Saminathan S ^d   Lian, Jane B ^c   Stein, Janet L ^c   Stein, Gary S ^c   Van Wijnen, Andre J ^c   Galindo, Mario ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; HETERODIMER; PROTEASOME; TRANSCRIPTION FACTOR RUNX2; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME DEGRADATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; MITOSIS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOSARCOMA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; RAT; TUMOR CELL LINE; UBIQUITINATION;

ANIMALS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; CYSTEINE PROTEINASE INHIBITORS; G1 PHASE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUPEPTINS; MICE; MITOSIS; OSTEOBLASTS; OSTEOSARCOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; UBIQUITINATION;

EID: 70449724816     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21894     Document Type: Article

References (53)

1. Bae SC, Choi JK. 2004. Tumor suppressor activity of RUNX3. Oncogene 23:4336-4340.
2. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. 2009. Repression of Runx2 by Androgen Receptor (AR) in osteoblasts and prostate cancer cells: AR Binds Runx2 and abrogates its binding to DNA. Mol Endocrinol 23:1203-1214.
3. Blyth K, Cameron ER, Neil JC. 2005. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 5:376-387. (Pubitemid 40637829)
4. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. 2006. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 66:2195-2201. (Pubitemid 43294930)
5. Cameron ER, Neil JC. 2004. The Runx genes: Lineage-specific oncogenes and tumor suppressors. Oncogene 23:4308-4314. (Pubitemid 38758596)
6. Das K, Leong D, Gupta A, Shen L, Putti TC, Stein GS, van Wijnen AJ, Salto-Tellez M. 2009. positive Association between nuclear Runx2 and estrogen-progesterone receptor gene expression characterizes a biological subtype of breast cancer. Eur JCancer [Epub ahead of print].
7. Eliseev RA, Dong YF, Sampson E, Zuscik MJ, Schwarz EM, O'Keefe RJ, Rosier RN, Drissi MH. 2008. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 27:3605-3614. (Pubitemid 351793799)
8. 1-related antiproliferative function in osteoblasts. J Biol Chem 280:20274-20285.
9. Galindo M, Kahler RA, Teplyuk NM, Stein JL, Lian JB, Stein GS, Westendorf JJ, van Wijnen AJ. 2007. Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts. J Mol Histol 38:501-506. (Pubitemid 350056782)
10. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, vanWijnen AJ, Stein JL, Stein GS, Lian JB. 2005. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.
11. Hajra A, Collins FS. 1996. Structure of the leukemia-associated human CBF gene. Genomics 38:107.
12. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R. 2004. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106-111. (Pubitemid 38160669)
13. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. 2001. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome- mediated degradation. EMBO J 20:723-733. (Pubitemid 32167637)
14. Javed A, Guo B, Hiebert S, Choi JY, Green J, Zhao SC, Osborne MA, Stifani S, Stein JL, Lian JB, van Wijnen AJ, Stein GS. 2000. Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha) ) dependent activation of tissue-specific gene transcription. J Cell Sci 113:2221-2231.
15. Kahler RA, Galindo M, Lian J, Stein GS, van Wijnen AJ, Westendorf JJ. 2006. Lymphocyte enhancer-binding factor 1 (Lef1) inhibits terminal differentiation of osteoblasts. J Cell Biochem 97:969-983.
16. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM. 2009. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837-851.
17. Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B. 2008. Modulation of Runx2 activity by estrogen receptor-alpha: Implications for osteoporosis and breast cancer. Endocrinology 149:5984-5995.
18. Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. 2007. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 67:11263-11271. (Pubitemid 350248552)
19. Kundu M, Javed A, Jeon JP, Horner A, Shum L, Eckhaus M, Muenke M, Lian JB, Yang Y, Nuckolls GH, Stein GS, Liu PP. 2002. Cbf beta interacts with Runx2 and has a critical role in bone development. Nat Genet 32:639-644.
20. Lien CY, Lee OK, Su Y. 2007. Cbfβ enhances the osteogenic differentiation of both human and mouse mesenchymal stem cells induced by Cbfa-1 via reducing its ubiquitination-mediated degradation. Stem Cells 25:1462-1468.
21. Liu F, Aubin JE, Malaval L. 2002. Expression of leukemia inhibitory factor (LIF)/interleukin-6, family cytokines and receptors during in vitro osteogenesis: Differential regulation by dexamethasone and LIF. Bone 31:212-219. (Pubitemid 34754450)
22. Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J, Xiao-Nan L, Ge G, Meyer R, Perlaky L, Hicks J, Chintagumpala M, Cai WW, Ladanyi M, Gorlick R, Lau CC, Pati D, Sheldon M, Rao PH. 2008. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 6:937-946.
23. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, Bennett E, Huang J, Kang Q, Jiang W, Su Y, Zhu GH, Yin H, He Y, Wang Y, Souris JS, Chen L, Zuo GW, Montag AG, Reid RR, Haydon RC, Luu HH, He TC. 2008. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 88:1264-1277.
24. Mallo M, Espinet B, Salido M, Ferrer A, Pedro C, Besses C, Pérez-Vila E, Serrano S, Florensa L, Solé F. 2007. Gain of multiple copies of the Cbfβ gene:A new genetic aberration in a case of granulocytic sarcoma. Cancer Genet Cytogenet 179:62-65. (Pubitemid 350018903)
25. Meyers S, Lenny N, Hiebert SW. 1995. The t (8;21) fusion protein interferes with AML-1b-dependent transcriptional activation. Mol Cell Biol 15:1974-1982.
26. Miyazono K, Maeda S, Imamura T. 2004. Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 23:4232-4237. (Pubitemid 38758589)
27. Nathan SS, Pereira BP, Zhou YF, GuptaA, Dombrowski C, Soong R, Pho RW, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. 2009. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36:153-158.
28. Nuthall HN, Joachim K, Palaparti A, Stifani S. 2002. A role for cell cicle-regulated phosphorilation in groucho-mediated transcriptional repression. J Biol Chem 277:51049-51057. (Pubitemid 36042277)
29. Ogawa E, Inuzuka M, Murayama M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K. 1993. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology 194:314-331. (Pubitemid 23211765)
30. Pereira BP, Zhou Y, Anurag G, Leong D, Aung KZ, Ling L, Pho RWH, Galindo M, Salto-tellez M, Stein GS, Simon C, van Wijnen AJ, Nathan SS. 2009. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol (manuscript submitted).
31. Pratap J, Galindo M, Zaidi SK, Vraidii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 2003. Cell growth regulatory role of Runx2 during proliferative expansion of pre-osteoblasts. Cancer Res 63:5357-5362. (Pubitemid 37139851)
32. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591. (Pubitemid 41369178)
33. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. 2006. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25:589-600. (Pubitemid 46071865)
34. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2008. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68:7795-7802.
35. Sadikovic B, Yoshimoto M, Chilton-Macneill S, Thorner P, Squire JA, Zielenska M. 2009. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 18:1962-1975.
36. Shen R, Wang X, Drissi H, Liu F, O'Keefe R, Chen D. 2006. Cyclin D1-CdK4 induce Runx2 Ubiquitination and degradation. J Biol Chem 281:16347-16353. (Pubitemid 43909583)
37. Speck NA, Stacy T. 1995. A new transcription factor family associatedwith human leukemias. Crit Rev Eukaryot Gene Expr 5:3337-3364.
38. Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E, Neil JC. 2007. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res 67:5126-5133. (Pubitemid 46997248)
39. Teplyuk NM, Galindo M, Teplyuk VI, Pratap J, Young DW, Lapointe D, Javed A, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 2008. Runx2 regulates G protein-coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem 283:27585-27597.
40. Teplyuk NM, Zhang Y, Lou Y, Hawse JR, Hassan MQ, Teplyuk VI, Pratap J, Galindo M, Stein JL, Stein GS, Lian JB, van Wijnen AJ. 2009a. The osteogenic transcription factor Runx2 controls genes involved in sterol/steroid metabolism, including Cyp11a1 in osteoblasts. Mol Endocrinol 23:849-861.
41. Teplyuk NM, Haupt LM, Ling L, Dombrowski C, Mun FK, Nathan SS, Lian JB, Stein JL, Stein GS, Cool SM, van Wijnen AJ. 2009b. The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts. J Cell Biochem 107:144-154.
42. Thomas D, Kansara M. 2006. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 98:757-769. (Pubitemid 43993394)
43. Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW. 2001. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 8:303-316.
44. Thomas D, Johnson S, Sims N, Trivett M, Slavin J, Rubin B, Waring P, McArthur G, Walkley C, Holloway A, Diyagama D, Grim J, Clurman B, Bowtell D, Lee J, Gutiérrez G, Piscopo D, Carty S, Hinds P. 2004. Terminal osteoblast differentiation, mediated by Runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 167:925-934.
45. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT. 2000. MAPK pathways activate and phosphorilate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 275:4453-4459. (Pubitemid 30094689)
46. Yoshida CA, Furuichi T, Fujita T, Fukuyama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T. 2002. Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet 32:633-638. (Pubitemid 35435176)
47. Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK, Lee SH, Yang X, Xie R, Javed A, Underwood JM, Furcinitti P, Imbalzano AN, Penman S, Nickerson JA, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 2007a. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445:442-446.
48. Young DW, Hassan MQ, Yang XQ, Galindo M, Javed A, Zaidi SK, Furcinitti P, Lapointe D, Montecino M, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 2007b. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci USA 104:3189-3194.
49. Yousfi M, Lasmoles F, Marie PJ. 2002. TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts. Biochem Biophys Res Commun 297:641-644.
50. Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2002. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA 99:8048-8053.
51. Zaidi SK, Young DW, Pockwinse SM, Javed A, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 2003. Mitotic partitioning and selective reorganization of tissue-specific transcription factors in progeny cells. Proc Natl Acad Sci USA 100:14852-14857. (Pubitemid 37517980)
52. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. 2007. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 104:19861-19866.
53. Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D. 2003. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 278:27939-27944 (Pubitemid 36899988)